ASCO 2007: What remains important for breast cancer systemic therapy in the routine setting?

被引:0
|
作者
Harbeck, Nadia [1 ]
Rack, Brigitte [1 ]
Janni, Wolfgang [1 ]
机构
[1] Univ Frauenklin Maistrasse LMU, Munich, Germany
关键词
ASCO; breast cancer; Lapatinib; taxanes; trastuzumab;
D O I
10.1159/000106770
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The 43rd ASCO Annual Meeting took place from June 1-5, 2007 at McCormick Place in Chicago, IL, USA. This year's meeting had the special theme of 'Translating Research into Practice', particularly featuring 445 abstracts on translational research in addition to approximately 2,000 abstracts presented on subjects like surgery, radiation therapy, chemotherapy, endocrine therapy, and targeted therapies. This short summary will focus on the two important breast cancer oral presentation sessions only, and will try to comment on the presented data with regard to their immediate impact on clinical practice. Many more research results regarding breast cancer were presented (all presentations will be available to the public from September 1, 2007 at wwwasco.org). In general, breast cancer data presented at this year's ASCO Annual Meeting confirmed current standards, and introduced promising new substances which may soon enter clinical practice. The 44th ASCO Annual Meeting will again be held in Chicago from May 30 to June 3, 2008. Those who do not want to wait another year may visit ASCO's first special Breast Cancer Symposium taking place September 7-8, 2007 in San Francisco, CA, USA. Whether this meeting will start a new tradition of a specialized ASCO breast cancer symposium, and how this development will eventually will impact on the regular San Antonio Breast Cancer Symposium in December, only time will tell.
引用
收藏
页码:241 / 243
页数:3
相关论文
共 50 条
  • [21] Preoperative Systemic Therapy for Breast Cancer
    Kodali, Abhigna
    Gadi, Vijayakrishna K.
    SURGICAL CLINICS OF NORTH AMERICA, 2023, 103 (01) : 201 - 217
  • [22] Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancerThe best of ASCO 2019
    Christoph Suppan
    Marija Balic
    memo - Magazine of European Medical Oncology, 2019, 12 : 312 - 314
  • [23] Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications
    Matyszewski, Arthur
    Czarnecka, Anna M.
    Stachowiak, Pawel
    Nowakowska, Marta
    Kornacewicz-Jach, Zdzislawa
    Kasprzak, Jaroslaw D.
    Szczylik, Cezary
    FUTURE ONCOLOGY, 2017, 13 (07) : 593 - 602
  • [24] What Are the Most Important New Targets in Breast Cancer?
    Cianfrocca, Mary
    CURRENT BREAST CANCER REPORTS, 2012, 4 (01) : 83 - 88
  • [25] The future of breast cancer systemic therapy: the next 10 years
    Telli, Melinda L.
    Sledge, George W.
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2015, 93 (02): : 119 - 125
  • [26] Advances in adjuvant and primary systemic therapy of early breast cancer
    Bischoff, Joachim
    Costa, Serban-Dan
    BREAST CARE, 2006, 1 (02) : 129 - 133
  • [27] What Are the Most Important New Targets in Breast Cancer?
    Mary Cianfrocca
    Current Breast Cancer Reports, 2012, 4 (1) : 83 - 88
  • [28] Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update
    Griggs, Jennifer J.
    Bohlke, Kari
    Balaban, Edward P.
    Dignam, James J.
    Hall, Evan T.
    Harvey, R. Donald
    Hecht, Diane P.
    Klute, Kelsey A.
    Morrison, Vicki A.
    Pini, T. May
    Rosner, Gary L.
    Runowicz, Carolyn D.
    Shayne, Michelle
    Sparreboom, Alex
    Turner, Sophia
    Zarwan, Corrine
    Lyman, Gary H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) : 2037 - +
  • [29] Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting
    Sorensen, Patricia Diana
    Jakobsen, Erik Hugger
    Langkjer, Sven Tyge
    Bokmand, Susanne
    Ostergaard, Birthe
    Olsen, Dorte Aalund
    Madsen, Jonna Skov
    Brandslund, Ivan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2009, 47 (09) : 1117 - 1123
  • [30] Radiotherapy and combined therapy in breast cancer: Standards and innovations in the adjuvant setting
    Belkacemi, Y.
    Gligorov, J.
    Chauvet, M. -P.
    Tsoutsou, P. G.
    Boussen, H.
    Bourgier, C.
    JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION, 2010, 39 (08): : F63 - F69